Early mortality in prophylactic implantable cardioverter-defibrillator recipients: Development and validation of a clinical risk score

Europace

Volumn 16, Issue 1, 2014, Pages 40-46

  Kraaier, Karin ^a   Scholten, Marcoen F ^a   Tijssen, Jan G P ^b   Theuns, Dominic A M J ^c   Jordaens, Luc J L M ^c   Wilde, Arthur A M ^b   Van Dessel, Pascal F H M ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dilated cardiomyopathy; Early mortality; Implantable cardioverter defibrillator; Ischaemic cardiomyopathy; Primary prevention; Risk score; Risk stratification

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RISK ASSESSMENT;

DILATED CARDIOMYOPATHY; EARLY MORTALITY; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ISCHAEMIC CARDIOMYOPATHY; PRIMARY PREVENTION; RISK SCORE; RISK STRATIFICATION;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84891349639     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut223     Document Type: Article

References (16)

1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 Guidelines for Management ofPatients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: areport ofthe American College ofCar-diology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone oran implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-37.
4. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006;151:397-403.
5. Stein KM, Mittal S, Gilliam FR, Gilligan DM, Zhong Q, Kraus SM et al. Predictors of early mortality in implantable cardioverter-defibrillator recipients. Europace 2009; 11:734-40.
6. Ertel D, Phatak K, Makati K, Holland M, Baig S, Kim MH et al. Predictors of early mortality in patients age 80 and older receiving implantable defibrillators. Pacing Clin Electrophysiol 2010;33:981-7.
7. Kao CW, Friedmann E, Thomas SA. Quality of life predicts one-year survival in patients with implantable cardioverter defibrillators. Qual Life Res 2010;19: 307-15.
8. Kramer DB, Friedman PA, Kallinen LM, Morrison TB, Crusan DJ, Hodge DO et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012; 9:42-6.
9. Chong D, Tan BY, Ho KL, Liew R, Teo WS, Ching CK. Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation. Europace 2013;15:508-14.
10. Duray GZ, Schmitt J, Richter S, Israel CW, Hohnloser SH. Arrhythmic death in implantable cardioverter defibrillator patients: a long-term study over a 10 year implantation period. Europace 2009;11:1462-8.
11. Brullmann S, Dichtl W, Paoli U, Haegeli L, Schmied C, Steffel J et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged ≥75 years versus those, 75 years. Am J Cardiol 2012;109:712-7.
12. Grimm W, Stula A, Sharkova J, Alter P, Maisch B. Outcomes of elderly recipients of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2007;30(Suppl 1): S134-8.
13. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
14. Cygankiewicz I, Gillespie J, Zareba W, Brown MW, Goldenberg I, Klein H et al. Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter- defibrillators. Heart Rhythm 2009;6:468-73.
15. Borleffs CJ, van Welsenes GH, van Bommel RJ, van der Velde ET, Bax JJ, van Erven L et al. Mortality risk score in primary prevention implantable cardioverter defibrilla-tor recipients with non-ischaemic or ischaemic heart disease. Eur Heart J 2010;31: 712-8.
16. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillatorimplantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 2012;60:1647-55.